S&P 500   3,976.80 (+0.15%)
DOW   32,431.21 (+0.60%)
QQQ   309.20 (-0.54%)
AAPL   158.67 (-0.99%)
MSFT   276.85 (-1.33%)
META   203.02 (-1.45%)
GOOGL   102.78 (-2.52%)
AMZN   98.33 (+0.20%)
TSLA   192.84 (+1.28%)
NVDA   265.15 (-0.99%)
NIO   8.99 (-0.88%)
BABA   86.08 (-0.94%)
AMD   96.96 (-1.01%)
T   18.93 (+1.72%)
F   11.58 (+0.61%)
MU   60.10 (-1.73%)
CGC   1.89 (-0.79%)
GE   93.34 (+2.16%)
DIS   95.75 (+1.78%)
AMC   4.52 (+1.12%)
PFE   40.29 (-0.25%)
PYPL   73.57 (-0.42%)
NFLX   328.21 (-0.05%)
S&P 500   3,976.80 (+0.15%)
DOW   32,431.21 (+0.60%)
QQQ   309.20 (-0.54%)
AAPL   158.67 (-0.99%)
MSFT   276.85 (-1.33%)
META   203.02 (-1.45%)
GOOGL   102.78 (-2.52%)
AMZN   98.33 (+0.20%)
TSLA   192.84 (+1.28%)
NVDA   265.15 (-0.99%)
NIO   8.99 (-0.88%)
BABA   86.08 (-0.94%)
AMD   96.96 (-1.01%)
T   18.93 (+1.72%)
F   11.58 (+0.61%)
MU   60.10 (-1.73%)
CGC   1.89 (-0.79%)
GE   93.34 (+2.16%)
DIS   95.75 (+1.78%)
AMC   4.52 (+1.12%)
PFE   40.29 (-0.25%)
PYPL   73.57 (-0.42%)
NFLX   328.21 (-0.05%)
S&P 500   3,976.80 (+0.15%)
DOW   32,431.21 (+0.60%)
QQQ   309.20 (-0.54%)
AAPL   158.67 (-0.99%)
MSFT   276.85 (-1.33%)
META   203.02 (-1.45%)
GOOGL   102.78 (-2.52%)
AMZN   98.33 (+0.20%)
TSLA   192.84 (+1.28%)
NVDA   265.15 (-0.99%)
NIO   8.99 (-0.88%)
BABA   86.08 (-0.94%)
AMD   96.96 (-1.01%)
T   18.93 (+1.72%)
F   11.58 (+0.61%)
MU   60.10 (-1.73%)
CGC   1.89 (-0.79%)
GE   93.34 (+2.16%)
DIS   95.75 (+1.78%)
AMC   4.52 (+1.12%)
PFE   40.29 (-0.25%)
PYPL   73.57 (-0.42%)
NFLX   328.21 (-0.05%)
S&P 500   3,976.80 (+0.15%)
DOW   32,431.21 (+0.60%)
QQQ   309.20 (-0.54%)
AAPL   158.67 (-0.99%)
MSFT   276.85 (-1.33%)
META   203.02 (-1.45%)
GOOGL   102.78 (-2.52%)
AMZN   98.33 (+0.20%)
TSLA   192.84 (+1.28%)
NVDA   265.15 (-0.99%)
NIO   8.99 (-0.88%)
BABA   86.08 (-0.94%)
AMD   96.96 (-1.01%)
T   18.93 (+1.72%)
F   11.58 (+0.61%)
MU   60.10 (-1.73%)
CGC   1.89 (-0.79%)
GE   93.34 (+2.16%)
DIS   95.75 (+1.78%)
AMC   4.52 (+1.12%)
PFE   40.29 (-0.25%)
PYPL   73.57 (-0.42%)
NFLX   328.21 (-0.05%)
NASDAQ:NBRV

Nabriva Therapeutics - NBRV Stock Forecast, Price & News

Notice: Trading of Nabriva Therapeutics halted at 09:35 AM EST due to "LULD pause".
$1.68
-0.07 (-4.13%)
(As of 03/27/2023 03:28 PM ET)
Add
Compare
Today's Range
$1.26
$1.81
50-Day Range
$1.49
$1.90
52-Week Range
$1.22
$12.80
Volume
44,027 shs
Average Volume
42,488 shs
Market Capitalization
$51.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Nabriva Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.00 Rating Score
Upside/​Downside
2,780.2% Upside
$50.00 Price Target
Short Interest
Healthy
0.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Nabriva Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($17.37) to ($8.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

668th out of 995 stocks

Pharmaceutical Preparations Industry

322nd out of 482 stocks


NBRV stock logo

About Nabriva Therapeutics (NASDAQ:NBRV) Stock

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
NBRV Nabriva Therapeutics plc
Nabriva Therapeutics Provides Corporate Update
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Nabriva's stock is up after sharing antibiotic news
See More Headlines
Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Company Calendar

Last Earnings
5/06/2021
Today
3/27/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBRV
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+2,930.3%
Consensus Rating
Reduce
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-49,450,000.00
Net Margins
-133.25%
Pretax Margin
-129.87%

Debt

Sales & Book Value

Annual Sales
$28.90 million
Book Value
$2.35 per share

Miscellaneous

Free Float
30,140,000
Market Cap
$50.56 million
Optionable
Optionable
Beta
1.53

Key Executives

  • John Christopher NaftzgerJohn Christopher Naftzger
    CEO, Secretary & General Counsel
  • Dan Dolan
    Chief Financial Officer
  • Christine Guico-Pabia
    Chief Medical Officer
  • Jodi VanDerveer
    Senior Vice President & Head-Human Resources
  • Kim Anderson
    Investor & Media Contact













NBRV Stock - Frequently Asked Questions

Should I buy or sell Nabriva Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" NBRV shares.
View NBRV analyst ratings
or view top-rated stocks.

What is Nabriva Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price objectives for Nabriva Therapeutics' shares. Their NBRV share price forecasts range from $50.00 to $50.00. On average, they expect the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 2,662.4% from the stock's current price.
View analysts price targets for NBRV
or view top-rated stocks among Wall Street analysts.

How have NBRV shares performed in 2023?

Nabriva Therapeutics' stock was trading at $1.89 at the start of the year. Since then, NBRV stock has decreased by 4.2% and is now trading at $1.81.
View the best growth stocks for 2023 here
.

When is Nabriva Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our NBRV earnings forecast
.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share for the quarter, topping analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 120.02% and a negative net margin of 133.25%.
Read the conference call transcript
.

When did Nabriva Therapeutics' stock split?

Shares of Nabriva Therapeutics reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Charles A Rowland Jr, Colin Md Broom, J Christopher Naftzger, Stephen W Webster, Theodore R Schroeder and Theodore R Schroeder.
View institutional ownership trends
.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $1.81.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $55.46 million and generates $28.90 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($19.71) on an earnings per share basis.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639.

This page (NASDAQ:NBRV) was last updated on 3/27/2023 by MarketBeat.com Staff